Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD)
Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1...
Ausführliche Beschreibung
Autor*in: |
Wolowski, A. [verfasserIn] Eger, T. [verfasserIn] Braas, R. [verfasserIn] Gohr, J. [verfasserIn] Weber, N. [verfasserIn] Witanski, K. [verfasserIn] Wörner, F. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Clinical Oral Investigations - Springer-Verlag, 2001, 24(2020), 4 vom: 16. Jan., Seite 1493-1497 |
---|---|
Übergeordnetes Werk: |
volume:24 ; year:2020 ; number:4 ; day:16 ; month:01 ; pages:1493-1497 |
Links: |
---|
DOI / URN: |
10.1007/s00784-019-03184-5 |
---|
Katalog-ID: |
SPR039269817 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR039269817 | ||
003 | DE-627 | ||
005 | 20230519153504.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00784-019-03184-5 |2 doi | |
035 | |a (DE-627)SPR039269817 | ||
035 | |a (SPR)s00784-019-03184-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wolowski, A. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. | ||
650 | 4 | |a CMD |7 (dpeaa)DE-He213 | |
650 | 4 | |a Splint therapy |7 (dpeaa)DE-He213 | |
650 | 4 | |a PTSD |7 (dpeaa)DE-He213 | |
650 | 4 | |a Bundeswehr soldiers |7 (dpeaa)DE-He213 | |
700 | 1 | |a Eger, T. |e verfasserin |4 aut | |
700 | 1 | |a Braas, R. |e verfasserin |4 aut | |
700 | 1 | |a Gohr, J. |e verfasserin |4 aut | |
700 | 1 | |a Weber, N. |e verfasserin |4 aut | |
700 | 1 | |a Witanski, K. |e verfasserin |4 aut | |
700 | 1 | |a Wörner, F. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical Oral Investigations |d Springer-Verlag, 2001 |g 24(2020), 4 vom: 16. Jan., Seite 1493-1497 |w (DE-627)SPR007794231 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2020 |g number:4 |g day:16 |g month:01 |g pages:1493-1497 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00784-019-03184-5 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 24 |j 2020 |e 4 |b 16 |c 01 |h 1493-1497 |
author_variant |
a w aw t e te r b rb j g jg n w nw k w kw f w fw |
---|---|
matchkey_str |
wolowskiaegertbraasrgohrjwebernwitanskik:2020----:ogemfetoslnteaynainsihotrua |
hierarchy_sort_str |
2020 |
publishDate |
2020 |
allfields |
10.1007/s00784-019-03184-5 doi (DE-627)SPR039269817 (SPR)s00784-019-03184-5-e DE-627 ger DE-627 rakwb eng Wolowski, A. verfasserin aut Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 Eger, T. verfasserin aut Braas, R. verfasserin aut Gohr, J. verfasserin aut Weber, N. verfasserin aut Witanski, K. verfasserin aut Wörner, F. verfasserin aut Enthalten in Clinical Oral Investigations Springer-Verlag, 2001 24(2020), 4 vom: 16. Jan., Seite 1493-1497 (DE-627)SPR007794231 nnns volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 https://dx.doi.org/10.1007/s00784-019-03184-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 24 2020 4 16 01 1493-1497 |
spelling |
10.1007/s00784-019-03184-5 doi (DE-627)SPR039269817 (SPR)s00784-019-03184-5-e DE-627 ger DE-627 rakwb eng Wolowski, A. verfasserin aut Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 Eger, T. verfasserin aut Braas, R. verfasserin aut Gohr, J. verfasserin aut Weber, N. verfasserin aut Witanski, K. verfasserin aut Wörner, F. verfasserin aut Enthalten in Clinical Oral Investigations Springer-Verlag, 2001 24(2020), 4 vom: 16. Jan., Seite 1493-1497 (DE-627)SPR007794231 nnns volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 https://dx.doi.org/10.1007/s00784-019-03184-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 24 2020 4 16 01 1493-1497 |
allfields_unstemmed |
10.1007/s00784-019-03184-5 doi (DE-627)SPR039269817 (SPR)s00784-019-03184-5-e DE-627 ger DE-627 rakwb eng Wolowski, A. verfasserin aut Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 Eger, T. verfasserin aut Braas, R. verfasserin aut Gohr, J. verfasserin aut Weber, N. verfasserin aut Witanski, K. verfasserin aut Wörner, F. verfasserin aut Enthalten in Clinical Oral Investigations Springer-Verlag, 2001 24(2020), 4 vom: 16. Jan., Seite 1493-1497 (DE-627)SPR007794231 nnns volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 https://dx.doi.org/10.1007/s00784-019-03184-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 24 2020 4 16 01 1493-1497 |
allfieldsGer |
10.1007/s00784-019-03184-5 doi (DE-627)SPR039269817 (SPR)s00784-019-03184-5-e DE-627 ger DE-627 rakwb eng Wolowski, A. verfasserin aut Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 Eger, T. verfasserin aut Braas, R. verfasserin aut Gohr, J. verfasserin aut Weber, N. verfasserin aut Witanski, K. verfasserin aut Wörner, F. verfasserin aut Enthalten in Clinical Oral Investigations Springer-Verlag, 2001 24(2020), 4 vom: 16. Jan., Seite 1493-1497 (DE-627)SPR007794231 nnns volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 https://dx.doi.org/10.1007/s00784-019-03184-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 24 2020 4 16 01 1493-1497 |
allfieldsSound |
10.1007/s00784-019-03184-5 doi (DE-627)SPR039269817 (SPR)s00784-019-03184-5-e DE-627 ger DE-627 rakwb eng Wolowski, A. verfasserin aut Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 Eger, T. verfasserin aut Braas, R. verfasserin aut Gohr, J. verfasserin aut Weber, N. verfasserin aut Witanski, K. verfasserin aut Wörner, F. verfasserin aut Enthalten in Clinical Oral Investigations Springer-Verlag, 2001 24(2020), 4 vom: 16. Jan., Seite 1493-1497 (DE-627)SPR007794231 nnns volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 https://dx.doi.org/10.1007/s00784-019-03184-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 24 2020 4 16 01 1493-1497 |
language |
English |
source |
Enthalten in Clinical Oral Investigations 24(2020), 4 vom: 16. Jan., Seite 1493-1497 volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 |
sourceStr |
Enthalten in Clinical Oral Investigations 24(2020), 4 vom: 16. Jan., Seite 1493-1497 volume:24 year:2020 number:4 day:16 month:01 pages:1493-1497 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
CMD Splint therapy PTSD Bundeswehr soldiers |
isfreeaccess_bool |
true |
container_title |
Clinical Oral Investigations |
authorswithroles_txt_mv |
Wolowski, A. @@aut@@ Eger, T. @@aut@@ Braas, R. @@aut@@ Gohr, J. @@aut@@ Weber, N. @@aut@@ Witanski, K. @@aut@@ Wörner, F. @@aut@@ |
publishDateDaySort_date |
2020-01-16T00:00:00Z |
hierarchy_top_id |
SPR007794231 |
id |
SPR039269817 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR039269817</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519153504.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00784-019-03184-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR039269817</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00784-019-03184-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wolowski, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CMD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Splint therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PTSD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bundeswehr soldiers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eger, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braas, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gohr, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weber, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witanski, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wörner, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical Oral Investigations</subfield><subfield code="d">Springer-Verlag, 2001</subfield><subfield code="g">24(2020), 4 vom: 16. Jan., Seite 1493-1497</subfield><subfield code="w">(DE-627)SPR007794231</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:4</subfield><subfield code="g">day:16</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:1493-1497</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00784-019-03184-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield><subfield code="e">4</subfield><subfield code="b">16</subfield><subfield code="c">01</subfield><subfield code="h">1493-1497</subfield></datafield></record></collection>
|
author |
Wolowski, A. |
spellingShingle |
Wolowski, A. misc CMD misc Splint therapy misc PTSD misc Bundeswehr soldiers Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
authorStr |
Wolowski, A. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR007794231 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) CMD (dpeaa)DE-He213 Splint therapy (dpeaa)DE-He213 PTSD (dpeaa)DE-He213 Bundeswehr soldiers (dpeaa)DE-He213 |
topic |
misc CMD misc Splint therapy misc PTSD misc Bundeswehr soldiers |
topic_unstemmed |
misc CMD misc Splint therapy misc PTSD misc Bundeswehr soldiers |
topic_browse |
misc CMD misc Splint therapy misc PTSD misc Bundeswehr soldiers |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Clinical Oral Investigations |
hierarchy_parent_id |
SPR007794231 |
hierarchy_top_title |
Clinical Oral Investigations |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)SPR007794231 |
title |
Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
ctrlnum |
(DE-627)SPR039269817 (SPR)s00784-019-03184-5-e |
title_full |
Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
author_sort |
Wolowski, A. |
journal |
Clinical Oral Investigations |
journalStr |
Clinical Oral Investigations |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
1493 |
author_browse |
Wolowski, A. Eger, T. Braas, R. Gohr, J. Weber, N. Witanski, K. Wörner, F. |
container_volume |
24 |
format_se |
Elektronische Aufsätze |
author-letter |
Wolowski, A. |
doi_str_mv |
10.1007/s00784-019-03184-5 |
author2-role |
verfasserin |
title_sort |
long-term effects of splint therapy in patients with posttraumatic stress disease (ptsd) |
title_auth |
Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
abstract |
Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. |
abstractGer |
Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. |
abstract_unstemmed |
Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
container_issue |
4 |
title_short |
Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD) |
url |
https://dx.doi.org/10.1007/s00784-019-03184-5 |
remote_bool |
true |
author2 |
Eger, T. Braas, R. Gohr, J. Weber, N. Witanski, K. Wörner, F. |
author2Str |
Eger, T. Braas, R. Gohr, J. Weber, N. Witanski, K. Wörner, F. |
ppnlink |
SPR007794231 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1007/s00784-019-03184-5 |
up_date |
2024-07-03T23:01:07.550Z |
_version_ |
1803600703125454848 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR039269817</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519153504.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00784-019-03184-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR039269817</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00784-019-03184-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wolowski, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term effects of splint therapy in patients with posttraumatic stress disease (PTSD)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives The aim of a pilot study was to clarify the question of whether mouth opening restrictions in patients with PTSD by means of splint therapy (st) show long-term therapeutic effects in the case of functional disorders. Material and methods In 31 of 36 inpatients (soldiers, average age 37.1 ± 7.3 years, 26.7 ± 2.1 teeth) with confirmed posttraumatic stress disorder, chronic pain intensity > 6 (visual analogue scale 0 to 10), the mouth opening was determined, and the functional status (RDC-TMD) was recorded. All participants received a splint that was worn at night. A control of the therapeutic effect of the splint occurred after 6 weeks, 3, 6, and 12 months. Results The mouth opening initially had an average of 30.9 ± 6.5 mm (median 31 mm). The pain intensity (PI) was reported to be on average VAS 8.3 ± 0.9, the chronic degree of pain according to von Korff was 3.9 ± 03. Six weeks after the st (n = 31), the average mouth opening was 49.5 ± 6.3 mm (median 51.5). PI was given as VAS 2.3 ± 1.1 on average. After 3, 6, and 12 months, 24, 15, and 14 subjects could be interviewed regarding PI. Based on the last examination date of all subjects, the average PI was given as 1.1 ± 0.9 (median 1). Conclusion The presented data show that the therapeutic short-term results achieved by means of a splint remain valid on the long term despite continued PTSD. Clinical relevance The presented study shows that patients will benefit in the long term from a splint and remain symptom-free, even if this mental illness persists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CMD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Splint therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PTSD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bundeswehr soldiers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eger, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braas, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gohr, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weber, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witanski, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wörner, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical Oral Investigations</subfield><subfield code="d">Springer-Verlag, 2001</subfield><subfield code="g">24(2020), 4 vom: 16. Jan., Seite 1493-1497</subfield><subfield code="w">(DE-627)SPR007794231</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:4</subfield><subfield code="g">day:16</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:1493-1497</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00784-019-03184-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2020</subfield><subfield code="e">4</subfield><subfield code="b">16</subfield><subfield code="c">01</subfield><subfield code="h">1493-1497</subfield></datafield></record></collection>
|
score |
7.4010544 |